Evidence map›Paper›PMID 35653427›Full record

ArticlePerfusion2023

COVID-19 outcomes of venovenous extracorporeal membrane oxygenation for acute respiratory failure vs historical cohort of non-COVID-19 viral infections.

Sagar B Dave, Ronald Rabinowitz, Aakash Shah, Ali Tabatabai, Samuel M Galvagno, Michael A Mazzeffi, Raymond Rector, David J Kaczorowski, Thomas M Scalea, Jay Menaker

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Perfusion, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Sagar B DaveDepartment of Emergency Medicine, Department of Anesthesiology, Division of Critical Care, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0001-8859-6491
Ronald RabinowitzDepartment of Medicine, Program in Trauma, R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Aakash ShahDepartment of Surgery, Division of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-2302-733X
Ali TabatabaiDepartment of Medicine, Division of Pulmonary and Critical Care, Program in Trauma, R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-5325-4907
Samuel M GalvagnoDepartment of Anesthesiology, Program in Trauma, R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-5563-4092
Michael A MazzeffiDepartment of Anesthesiology and Critical Care Medicine, George Washington School of Medicine and Health Sciences, Washington, DC, USA.ORCID 0000-0003-2955-4915
Raymond RectorPerfusion Services, University of Maryland Medical Center, Baltimore, MD, USA.
David J KaczorowskiDepartment of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Thomas M ScaleaDepartment of Surgery, Program in Trauma, R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Jay MenakerDepartment of Surgery, Johns Hopkins Medicine, Howard County General Hospital, Columbia, MD, USA.
University of Maryland, Baltimore · USEmory University · USGeorge Washington University · USJohns Hopkins University · USUniversity of Pittsburgh Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVeno-venous extracorporeal membrane oxygenation (VV ECMO) has become a support modality for patients with acute respiratory failure refractory to standard therapies. VV ECMO has been increasingly used during the current COVID-19 pandemic for patients with refractory respiratory failure. The object of this study was to evaluate the outcomes of VV ECMO in patients with COVID-19 compared to patients with non-COVID-19 viral infections.

methodsWe retrospectively reviewed all patients supported with VV ECMO between 8/2014 and 8/2020 whose etiology of illness was a viral pulmonary infection. The primary outcome of this study was to evaluate in-hospital mortality. The secondary outcomes included length of ECMO course, ventilator duration, hospital length of stay, incidence of adverse events through ECMO course.

resultsEighty-nine patients were included (35 COVID-19 vs 54 non-COVID-19). Forty (74%) of the non-COVID-19 patients had influenza virus. Prior to cannulation, COVID-19 patients had longer ventilator duration (3 vs 1 day,

conclusionCOVID-19 patients supported with VV ECMO have a higher mortality than non-COVID-19 patients. While COVID-19 survivors had significantly longer VV ECMO runs than non-COVID-19 survivors, HLOS was similar. This data add to a growing body of literature supporting the use of ECMO for potentially reversible causes of respiratory failure.

Indexed as

COVID-19Extracorporeal Membrane OxygenationRespiratory Distress SyndromeRespiratory InsufficiencyHumansPandemicsRetrospective Studiesacute respiratory distress syndromeacute respiratory failureCOVID-19critical careextracorporeal membrane oxygenationinfluenzaviral

Identifiers

PMID35653427
PMCPMC9168413
OpenAlexW4281819280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.